Antiviral therapies and prospects for a cure of chronic hepatitis B.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cold Spring Harbor Perspectives in Medicine

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1101/cshperspect.a021501PMID 25833942PMCID PMC4382723
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• At the tipping point for epigenetic therapies in cancer.

  2014cited by this paper
• Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)

  2014cited by this paper
• No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B

  2014cited by this paper
• HBeAg‐positive chronic hepatitis B: Why do I treat my patients with Nucleos(t)ide Analogs?

  2014influential reference
• Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.

  2014cited by this paper
• Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta

  2014cited by this paper
• Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses

  2014cited by this paper
• Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.

  2014cited by this paper
• Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA

  2014cited by this paper
• Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

  2014cited by this paper
• Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems

  2014cited by this paper
• Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.

  2014cited by this paper
• HBeAg‐negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?

  2014influential reference
• HBeAg‐negative chronic hepatitis B: why do I treat my patients with pegylated interferon‐alfa?

  2014cited by this paper
• Hepatic immune regulation and its involvement in viral hepatitis infection.

  2014cited by this paper
• HBeAg‐positive chronic hepatitis B: why do I treat my patients with pegylated interferon?

  2014cited by this paper
• Telbivudine improves renal function in patients with chronic hepatitis B.

  2014cited by this paper
• The 104‐week efficacy and safety of telbivudine‐based optimization strategy in chronic hepatitis B patients: A randomized, controlled study

  2014cited by this paper
• Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.

  2014cited by this paper
• The promise and failures of epigenetic therapies for cancer treatment.

  2014cited by this paper
• Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

  2014cited by this paper
• Strategies to inhibit entry of HBV and HDV into hepatocytes.

  2014cited by this paper
• Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease

  2014cited by this paper
• Combination of DNA Prime – Adenovirus Boost Immunization with Entecavir Elicits Sustained Control of Chronic Hepatitis B in the Woodchuck Model

  2013cited by this paper
• Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B.

  2013cited by this paper
• GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.

  2013cited by this paper
• Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: lessons from experimental and clinical studies.

  2013cited by this paper
• Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

  2013influential reference
• Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?

  2013cited by this paper
• Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.

  2013cited by this paper
• Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.

  2013cited by this paper
• Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.

  2013cited by this paper
• Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

  2013cited by this paper
• Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from mauritius island

  2013cited by this paper
• Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy

  2013cited by this paper
• Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

  2013cited by this paper
• Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection

  2013cited by this paper
• In vitro phenotyping of recombinant hepatitis B virus containing the polymerase/reverse transcriptase gene from clinical isolates.

  2013cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation

  2012cited by this paper
• Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.

  2012cited by this paper
• Effectiveness of hepatitis B treatment in clinical practice.

  2012cited by this paper
• New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives

  2012cited by this paper
• New perspectives in the therapy of chronic hepatitis B

  2012cited by this paper
• Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

  2012cited by this paper
• IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.

  2012cited by this paper
• Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation

  2012cited by this paper
• Role of Toll-like receptor 2 in the immune response against hepadnaviral infection.

  2012cited by this paper
• The Role of Adherence in Virological Suppression in Patients Receiving Anti-HBV Analogues

  2012cited by this paper
• Are novel combination therapies needed for chronic hepatitis B?

  2012cited by this paper
• Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

  2012cited by this paper
• Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.

  2012cited by this paper
• Interplay between hepatitis B virus and TLR2-mediated innate immune responses: can restoration of TLR2 functions be a new therapeutic option?

  2012cited by this paper
• Selection of chronic hepatitis B therapy with high barrier to resistance.

  2012influential reference
• Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

  2012cited by this paper
• The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.

  2011cited by this paper
• Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

  2011cited by this paper
• Reasons to consider earlier treatment of chronic HBV infections

  2011cited by this paper
• Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study

  2011cited by this paper
• Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

  2011influential reference
• Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open‐label study

  2011cited by this paper
• Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges.

  2011cited by this paper
• Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection.

  2011cited by this paper
• Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease

  2011cited by this paper
• Hepatitis: Treatment failure in chronic hepatitis B

  2011cited by this paper
• Synthesis and Biological Evaluation of Triazolo-pyrimidine Derivatives as Novel Inhibitors of Hepatitis B Virus Surface Antigen (HBsAg) Secretion

  2010cited by this paper
• Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B

  2010cited by this paper
• Virus assembly, allostery and antivirals

  2010cited by this paper
• Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B

  2010cited by this paper
• A promiscuous α-helical motif anchors viral hijackers and substrate receptors to the CUL4–DDB1 ubiquitin ligase machinery

  2010cited by this paper
• Mechanism for CCC DNA Synthesis in Hepadnaviruses

  2009cited by this paper
• Hepatitis B virus resistance to nucleos(t)ide analogues.

  2009influential reference
• Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function

  2009cited by this paper
• Immune selection during chronic hepadnavirus infection

  2008cited by this paper
• Interferon-inducible antiviral effectors

  2008cited by this paper
• Zinc Finger Proteins Designed To Specifically Target Duck Hepatitis B Virus Covalently Closed Circular DNA Inhibit Viral Transcription in Tissue Culture

  2008cited by this paper
• Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.

  2008cited by this paper
• Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein

  2008cited by this paper
• The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

  2008cited by this paper
• Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants

  2008cited by this paper
• Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

  2008cited by this paper
• Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity.

  2007cited by this paper
• Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

  2007cited by this paper
• Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.

  2007cited by this paper
• The clinical significance of persistently normal ALT in chronic hepatitis B infection.

  2007cited by this paper
• Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

  2006cited by this paper
• A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

  2006cited by this paper
• Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery

  2006cited by this paper
• Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

  2006cited by this paper
• Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure.

  2005cited by this paper
• Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing.

  2005cited by this paper
• Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

  2005cited by this paper
• Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

  2005cited by this paper
• Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.

  2005cited by this paper
• Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

  2004cited by this paper
• Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

  2004cited by this paper
• Lamivudine for patients with chronic hepatitis B and advanced liver disease.

  2004influential reference
• Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

  2003cited by this paper
• Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids

  2003cited by this paper
• Histological outcome during long-term lamivudine therapy.

  2003cited by this paper

• Discovery and mechanism verification of first-in-class hydrophobic tagging-based degraders of HBV core protein

  2025cites this paper
• Inhibiting silencing information regulator 1 is conducive to the suppression of hepatitis B virus replication by entecavir.

  2025cites this paper
• Antibacterial and antiviral properties of punicalagin (Review)

  2025cites this paper
• Treatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study

  2025cites this paper
• New Dimensions In Viral Hepatitis Research: Advancements, Challenges, And Future Prospects

  2025cites this paper
• Interferon alpha-inducible protein 27 (IFI27) inhibits hepatitis B virus (HBV) transcription through downregulating cellular transcription factor C/EBPα

  2025cites this paper
• mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress

  2025cites this paper
• Cumulative Hepatitis B Surface Antigen/Hepatitis B Virus DNA Ratio in Immune-tolerant Hepatitis B Patients: A 10-year Follow-up Study

  2025cites this paper
• Novel NTCP ligand dimeric bile acid conjugated with ASO reduce hepatitis B virus surface antigen in vivo.

  2024cites this paper
• Clinical implications of hepatitis B virus core antigen‐mediated immunopathologic T cell responses in chronic hepatitis B

  2024cites this paper
• Discovery of pentacyclic triterpene conjugates as HBV polymerase/NTCP dual-targeting inhibitors with potent anti-HBV activities.

  2024cites this paper
• Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

  2024cites this paper
• Mechanistic modeling to understand variability in responses to chronic Hepatitis B treatment

  2024cites this paper
• Detection of hepatitis B virus genotypes in a group of hepatitis B virus-infected patients in central and northern Sri Lanka

  2024cites this paper
• Regulation of Hepatitis B Virus Replication by Modulating Endoplasmic Reticulum Stress (ER-Stress)

  2024cites this paper
• Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection

  2023cites this paper
• Computer-aided drug design in seeking viral capsid modulators.

  2023cites this paper
• Spectrum of Disease Activity in Incidentally Positive HBsAg Patients in Eastern Uttar Pradesh

  2023cites this paper
• In vitro evaluation of tropolone absorption, metabolism, and clearance.

  2023cites this paper
• Discovery of carboxyl-containing heteroaryldihydropyrimidine derivatives as novel HBV capsid assembly modulators with significantly improved metabolic stability.

  2023cites this paper
• Genome-wide CRISPR screens and their applications in infectious disease

  2023cites this paper
• Development of anti-HBV agents targeting HBV capsid proteins.

  2023cites this paper
• Antisense oligonucleotides: a promising therapeutic option against infectious diseases

  2023cites this paper
• Therapeutic Advances in Viral Hepatitis A–E

  2022cites this paper
• Inhibitory activities of Ranunculus japonicus Thunb. ethanol extract against hepatitis B virus

  2022cites this paper
• Role of bioactive compounds in the treatment of hepatitis: A review

  2022cites this paper
• Compound IMB-Z inhibits hepatitis B virus replication through increasing APOBEC3G expression and incorporation into viral nucleocapsids.

  2022cites this paper
• EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B

  2022cites this paper
• Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection.

  2022cites this paper
• Antiviral activities of Polygonum perfoliatum L. extract and related phenolic acid constituents against hepatitis B virus

  2022cites this paper
• Targeting lipid biosynthesis pathways for hepatitis B virus cure

  2022cites this paper
• Immune therapies against chronic hepatitis B

  2022cites this paper
• Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo

  2022cites this paper
• T follicular helper cells improve the response of patients with chronic hepatitis B to interferon by promoting HBsAb production

  2022cites this paper
• Novel chimeric vectors harboring hepatitis B viral promoter and reporter gene demonstrated liver-specific significance

  2022cites this paper
• Serum gamma-glutamyl transpeptidase-to-platelet ratio (GPR) can predict the prognosis of hepatocellular carcinoma: a meta-analysis and systematic review

  2021cites this paper
• Knowledge, Attitude and Practices of Dental Practitioners against Hepatitis B in District Faisalabad

  2021cites this paper
• Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical

  2021cites this paper
• Host-cell interactions in HBV infection and pathogenesis: the emerging role of m6A modification

  2021cites this paper
• Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial

  2021cites this paper
• Dynamics of cellular immune responses in recipients of renal allografts positive for hepatitis B surface antigen.

  2021cites this paper
• Clinical Study of Single‐Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B

  2021cites this paper
• Achieving a Cure: The Next Frontier in Hepatitis B Treatment

  2021cites this paper
• Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B

  2021cites this paper
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers

  2021cites this paper
• A hepatitis B virus causes chronic infections in equids worldwide

  2021cites this paper
• Assessing potential cures: are there distinctive elements of value beyond health gain?

  2021cites this paper
• Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes

  2021cites this paper
• The cooperative complex of Argonaute-2/MicroRNA-146a regulates Hepatitis B Virus replication through FEN1

  2020cites this paper
• Discovery of (1H-Pyrazolo[3,4-c]pyridin-5-yl)sulfonamide Analogs as Hepatitis B Virus Capsid Assembly Modulators by Conformation Constraint.

  2020cites this paper
• COVID-19 and Possible Pharmacological Preventive Options

  2020cites this paper
• Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment

  2020cites this paper
• An Intracellular Model of Hepatitis B Viral Infection: An In Silico Platform for Comparing Therapeutic Strategies

  2020cites this paper
• The 25(OH)Vitamin D Status Affected the Effectiveness of Oligo Fucoidan in Patients with Chronic Hepatitis B Virus Infection with Immune Tolerance Phase

  2020cites this paper
• Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity.

  2020cites this paper
• New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation

  2020cites this paper
• Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro.

  2020cites this paper
• Will we need novel combinations to cure HBV infection?

  2020cites this paper
• Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection

  2020cites this paper
• Combination of saikosaponin c and telbivudine synergistically enhances the anti-HBV activity

  2020cites this paper
• Hepatitis B, New Antiviral Targets

  2020cites this paper
• Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production

  2020cites this paper
• Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731

  2020cites this paper
• Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents

  2020cites this paper
• The cooperative complex of Argonaute-2 and microRNA-146a regulates hepatitis B virus replication through flap endonuclease 1.

  2020cites this paper
• Interferon: Role in health, current trends and therapeutic potentials

  2020cites this paper
• A Telomerase-Derived Peptide Exerts an Anti-Hepatitis B Virus Effect via Mitochondrial DNA Stress-Dependent Type I Interferon Production

  2020cites this paper
• Prevention Strategies for Hepatocellular Carcinoma

  2019cites this paper
• Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development.

  2019cites this paper
• PAPD5/7 Are Host Factors That Are Required for Hepatitis B Virus RNA Stabilization

  2019cites this paper
• PASylated interferon &agr; efficiently suppresses hepatitis B virus and induces anti‐HBs seroconversion in HBV‐transgenic mice

  2019cites this paper
• Biological basis for functional cure of chronic hepatitis B

  2019cites this paper
• Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine‐resistant HBV isolate

  2019cites this paper
• Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate

  2019cites this paper
• Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

  2019cites this paper
• Shedding light on RNaseH: a promising target for hepatitis B virus (HBV)

  2019cites this paper
• Therapeutic management with biological anti-TNF-α agent in severe psoriasis associated with chronic hepatitis B: A case report.

  2019cites this paper
• A peptide-based inhibitor of gp96 suppresses HBsAg expression and HBV replication by upregulation of p53.

  2019cites this paper
• Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure

  2019cites this paper
• Revisiting Hepatitis B Virus: Challenges of Curative Therapies

  2019cites this paper
• Hepatocellular Carcinoma: Translational Precision Medicine Approaches

  2019cites this paper
• Immunological Characterization of Mucosal-Associated Invariant T (MAIT) Cells in chronically Hepatitis B infected patients

  2019cites this paper
• Niacin analogue, 6-Aminonicotinamide, a novel inhibitor of hepatitis B virus replication and HBsAg production

  2019cites this paper
• Sequential drug delivery for liver diseases.

  2019cites this paper
• A genome-wide CRISPR screen identifies ZCCHC14 as a host factor required for hepatitis B surface antigen production

  2019cites this paper
• Autophagy in hepatitis B or C virus infection: An incubator and a potential therapeutic target.

  2019cites this paper
• Value Assessment Methods and Pricing Recommendations for Potential Cures: A Technical Brief

  2019cites this paper
• What is changed in HBV molecular epidemiology in Italy?

  2018cites this paper
• ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection.

  2018cites this paper
• Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients.

  2018cites this paper
• Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action.

  2018cites this paper
• Hepatitis B virus infection: Defective surface antigen expression and pathogenesis

  2018cites this paper
• Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle

  2018cites this paper
• A Highly Sensitive and Robust Method for Hepatitis B Virus Covalently Closed Circular DNA Detection in Single Cells and Serum.

  2018cites this paper
• Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo

  2018cites this paper
• Combination of Simvastatin and Entecavir for Chronic Hepatitis B : A Phase 1 Trial

  2018cites this paper
• Divergent impact of gender in advancement of liver injuries, diseases, and carcinogenesis.

  2018cites this paper
• Current and future directions of management of hepatitis B: steps toward a cure

  2018cites this paper
• Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells

  2018cites this paper
• Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination.

  2018cites this paper